Aptimmune was formed in 2010 and specializes in the development and application of prophylactic measures against viral diseases of swine. Chief Scientific Officer, Dr. Federico Zuckermann, and full-time facility member at the University of Illinois, is the inventor of the patented vaccine technologies.

Just last year the small team raised their first round of funding and brought on CEO, Aaron Gilbertie, to help lead the company through the development, product registration and commercialization of Aptimmune’s vaccines. I met Aaron during the recent World Pork Expo and sat down with him to learn more. “Today we are primarily focused on two viral pathogens Porcine Reproductive and Respiratory Syndrome (PRRS) virus and influenza. The two most costly pathogens affecting pigs today.”

The applicator is already available commercially today. Aaron said the application process is very similar to giving an injection, but instead it is a spray in the nose using a typical multi-dose syringe.

“We expect to launch our first autogenous product line for PRRS this fall and follow with our first influenza vaccine in Q1.” Aaron added that they will not only be focusing distribution to the end users, but also the veterinarians. “It is a very technical product. It’s a new product. We think it’s exciting, but veterinarians will really be the ones who determine how it’s used.”

Listen to my complete interview with Aaron to learn more: Interview with Aaron Gilbertie, CEO, Aptimmune

View and download photos from the event here:2016 World Pork Expo Photo Album